Published in PLoS One on October 02, 2015
FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol (2007) 7.94
Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov (2003) 6.66
Convergent solutions to binding at a protein-protein interface. Science (2000) 4.47
Metabolic properties of IgG subclasses in man. J Clin Invest (1970) 3.48
The third IgG-binding domain from streptococcal protein G. An analysis by X-ray crystallography of the structure alone and in a complex with Fab. J Mol Biol (1994) 2.68
The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med (2003) 2.63
Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res (2009) 2.58
Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy. Proc Natl Acad Sci U S A (2007) 2.56
Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J Immunol (2004) 2.30
Crystal structure of the C2 fragment of streptococcal protein G in complex with the Fc domain of human IgG. Structure (1995) 1.86
A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol (2009) 1.77
Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol (2011) 1.58
PK modulation of haptenylated peptides via non-covalent antibody complexation. J Control Release (2013) 1.46
Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem (2007) 1.36
Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assay. J Immunol Methods (1997) 1.26
Bispecific antibodies for cancer immunotherapy: Current perspectives. BioDrugs (2010) 1.24
Optimizing pH response of affinity between protein G and IgG Fc: how electrostatic modulations affect protein-protein interactions. J Biol Chem (2009) 1.11
Structural insights into neonatal Fc receptor-based recycling mechanisms. J Biol Chem (2014) 1.10
Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins. Vaccine (2005) 1.09
The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. Protein Eng Des Sel (2010) 1.06
The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J Lab Clin Med (1988) 1.06
Streptococcal protein G has affinity for both Fab- and Fc-fragments of human IgG. Mol Immunol (1988) 1.01
N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. J Biol Chem (2008) 0.98
Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains. J Biol Chem (2011) 0.93
pH-selective mutagenesis of protein-protein interfaces: in silico design of therapeutic antibodies with prolonged half-life. Proteins (2013) 0.92
Drug development: longer-lived proteins. Chem Soc Rev (2012) 0.91
Modulating the pharmacokinetics of therapeutic antibodies. Biotechnol Lett (2010) 0.87
Retargeting serum immunoglobulin with bispecific diabodies. Nat Biotechnol (1997) 0.85
Human autoimmune anti-proteinase 3 scFv from a phage display library. Clin Exp Immunol (1997) 0.85
Longer action means better drug: tuning up protein therapeutics. Biotechnol Adv (2011) 0.84
An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF action. Protein Eng Des Sel (2013) 0.80
Fusion of a short peptide that binds immunoglobulin G to a recombinant protein substantially increases its plasma half-life in mice. PLoS One (2014) 0.80
Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal protein A. Protein Eng Des Sel (2012) 0.79
Tumor-antigen-binding bispecific antibodies for cancer treatment. Semin Oncol (2014) 0.86
Antitumor Activity of a Mesenchymal Stem Cell Line Stably Secreting a Tumor-Targeted TNF-Related Apoptosis-Inducing Ligand Fusion Protein. Front Immunol (2017) 0.75